From the Department of Medicine (N.A.B., L.F., D.S.) and Department of Obstetrics and Gynecology (K.L.C., R.W.), Columbia University Medical Center, New York, NY; Department of Economics, California Polytechnic State University, San Luis Obispo (J.J.W.); Department of Pediatrics, University of Tennessee Health Science Center, Memphis (B.S.A.); and Department of Medicine (S.O.), Department of Biostatistics (G.C.), Department of Epidemiology (P.M.), and Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama at Birmingham.
Hypertension. 2018 Feb;71(2):326-335. doi: 10.1161/HYPERTENSIONAHA.117.10295. Epub 2017 Dec 11.
The accurate measurement of blood pressure (BP) in pregnancy is essential to guide medical decision making that affects both mother and fetus. The aim of this systematic review was to determine the accuracy of ambulatory, home, and clinic BP measurement devices in pregnant women. We searched Ovid MEDLINE, The Cochrane Library, EMBASE, CINAHL EBSCO, ClinicalTrials.gov, International Clinical Trials Registry Platform, and dabl from inception through August 3, 2017 for articles that assessed the validity of an upper arm BP measurement device against a mercury sphygmomanometer in pregnant women. Two independent investigators determined eligibility, extracted data, and adjudicated protocol violations. From 1798 potential articles identified, 41, that assessed 28 devices, met the inclusion criteria. Most articles (n=32) followed a standard or modified American National Standards Institute/Association for the Advancement of Medical Instrumentation/International Organization for Standardization, British Hypertension Society, or European Society of Hypertension validation protocol. Several articles described the results of validation studies performed on >1 device (n=7) or in >1 population of pregnant women (n=12), comprising 64 pairwise validity assessments. The device was validated in 61% (32 of 52) of studies which used a standard or modified protocol. Only 34% (11 of 32) of the studies wherein the device was successfully validated were performed without a protocol violation. Given the implications of inaccurate BP measurement in pregnant women, healthcare providers should be aware of and try to use the BP measurement devices which have been properly validated in this population.
准确测量妊娠期间的血压(BP)对于指导影响母婴双方的医疗决策至关重要。本系统评价的目的是确定在孕妇中使用动态血压监测仪、家庭血压监测仪和诊所血压监测仪的准确性。我们检索了 Ovid MEDLINE、The Cochrane Library、EMBASE、CINAHL EBSCO、ClinicalTrials.gov、International Clinical Trials Registry Platform 和 dabl,从建库至 2017 年 8 月 3 日,以评估在上臂测量 BP 设备的准确性,将其与水银血压计进行比较,这些文章评估了孕妇的血压测量设备。两名独立的调查员确定了合格性、提取了数据,并对违反方案的情况进行了裁决。从 1798 篇潜在的文章中,有 41 篇评估了 28 种设备,符合纳入标准。大多数文章(n=32)遵循了美国国家标准协会/医学仪器促进协会/国际标准化组织、英国高血压学会或欧洲高血压学会的标准或改良验证方案。有几篇文章描述了在>1 种设备(n=7)或在>1 个孕妇人群(n=12)上进行的验证研究的结果,包括 64 项成对有效性评估。在使用标准或改良方案的 52 项研究中,有 61%(32 项)对设备进行了验证。在成功验证设备的 32 项研究中,只有 34%(11 项)没有违反方案。鉴于在孕妇中测量血压不准确的影响,医疗保健提供者应该意识到并尝试使用在该人群中经过适当验证的血压测量设备。